Palo Alto Investors
Palo Alto Investors is an investment advisor founded in 1989 with $1.5 billion under management. The firm's approach is deeply fundamental and their goal is to serve clients by delivering sustained, high rates of return over time. The firm offers several strategies, each of which has the same basic approach and goal, but focus on different market segments.
The firm's investment focus is predominantly Micro-Cap & Small-Cap U.S. Equities and sectors include Technology, Healthcare, Energy, Consumer, & Financial Services.
View Older Stories
-
AnaptysBio board approves First Tracks Biotherapeutics spin-off
-
Form 13F-HR Palo Alto Investors LP For: Dec 31
-
Form SCHEDULE 13G eHealth, Inc. Filed by: Palo Alto Investors LP
-
Form 13F-HR Palo Alto Investors LP For: Sep 30
-
Oruka Therapeutics raises $180 million in private placement
-
Form N-PX Palo Alto Investors LP For: Jun 30
-
Form 13F-HR Palo Alto Investors LP For: Jun 30
-
Form 13F-HR Palo Alto Investors LP For: Mar 31
-
Form 13F-HR Palo Alto Investors LP For: Dec 31
-
Form SCHEDULE 13G/A Revance Therapeutics, Filed by: Palo Alto Investors LP
-
Form 13F-HR Palo Alto Investors LP For: Sep 30
-
Form N-PX Palo Alto Investors LP For: Jun 30
-
Form 13F-HR Palo Alto Investors LP For: Jun 30
-
Form 13F-HR Palo Alto Investors LP For: Mar 31
-
Kamari Pharma Appoints Dr. John Doux to its Board of Directors
-
Form 13F-HR/A Palo Alto Investors LP For: Dec 31
-
Form SC 13G/A Revance Therapeutics, Filed by: Palo Alto Investors LP
-
Form SC 13G/A eHealth, Inc. Filed by: Palo Alto Investors LP
-
Form SC 13G/A Karyopharm Therapeutics Filed by: Palo Alto Investors LP
-
Form 13F-HR Palo Alto Investors LP For: Dec 31
-
Form 13F-HR Palo Alto Investors LP For: Sep 30
-
VYNE Therapeutics (VYNE) Announces Private Placement of $88 Million
-
VYNE Therapeutics Announces Private Placement of $88 Million
-
Form 13F-HR Palo Alto Investors LP For: Jun 30
-
Gossamer Bio Inc. (GOSS) Announces $212M Private Placement Financing
-
Gossamer Bio Announces $212 Million Private Placement Financing
-
Form 13F-HR Palo Alto Investors LP For: Mar 31
-
Form SC 13G/A ALIMERA SCIENCES INC Filed by: Palo Alto Investors LP
-
Form 4 ALIMERA SCIENCES INC For: Mar 24 Filed by: Palo Alto Investors LP
-
Form 13F-HR Palo Alto Investors LP For: Dec 31
-
Form SC 13G/A Revance Therapeutics, Filed by: Palo Alto Investors LP
-
Form SC 13G/A eHealth, Inc. Filed by: Palo Alto Investors LP
-
Form SC 13G/A Vanda Pharmaceuticals Filed by: Palo Alto Investors LP
-
Form SC 13G/A Karyopharm Therapeutics Filed by: Palo Alto Investors LP
-
Form SC 13G/A INSMED Inc Filed by: Palo Alto Investors LP
-
Form SC 13G/A Epizyme, Inc. Filed by: Palo Alto Investors LP
-
Form SC 13G/A ALIMERA SCIENCES INC Filed by: Palo Alto Investors LP
-
ACELYRIN, INC. Furthers Leadership Position in Immunology with Transformative Acquisition of ValenzaBio
-
Form 13F-HR Palo Alto Investors LP For: Sep 30
-
Form 13F-HR Palo Alto Investors LP For: Jun 30
-
Form 13F-HR Palo Alto Investors LP For: Mar 31
-
Peak Bio to Go Public Via Merger with Ignyte Acquisition Corp (IGNY) in $278M Deal
-
Peak Bio and Ignyte Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Oncology and Inflammation Company
-
Form SC 13G/A Epizyme, Inc. Filed by: Palo Alto Investors LP
-
Form SC 13G/A INSMED Inc Filed by: Palo Alto Investors LP
-
Form SC 13G/A Clovis Oncology, Inc. Filed by: Palo Alto Investors LP
-
Form SC 13G/A Revance Therapeutics, Filed by: Palo Alto Investors LP
-
Form SC 13G/A eHealth, Inc. Filed by: Palo Alto Investors LP
-
Form SC 13G/A Karyopharm Therapeutics Filed by: Palo Alto Investors LP
-
Form SC 13G/A Vanda Pharmaceuticals Filed by: Palo Alto Investors LP

